Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OneMedNet Corp filings document the public-company reporting record for a healthcare data business with common stock and redeemable warrants. Recent 8-K reports cover Nasdaq continued-listing matters, including minimum bid price and market-value compliance notices, along with other material events affecting the company’s public listing status.
Proxy materials describe annual meeting procedures, stockholder voting matters, board composition, and governance disclosures. The filing record also identifies the company’s capital securities, including common stock and redeemable warrants exercisable for common shares, and records director-related governance updates through current reports.
OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.
OneMedNet Corporation (ONMD) filed a prospectus supplement registering up to 11,680,535 shares of common stock and incorporating its Form 10‑Q for the quarter ended June 30, 2026.
For Q2 2026, revenue was $292 thousand (up from $155 thousand a year earlier), driven by higher data delivery revenue, but the company posted a net loss of $2,172 thousand and a six‑month net loss of $4,625 thousand. Cash and cash equivalents were $358 thousand against $4,882 thousand of total liabilities and a stockholders’ deficit of $3,518 thousand, and management states there is substantial doubt about the company’s ability to continue as a going concern.
ONMD no longer holds Bitcoin, having liquidated prior crypto holdings in 2026. Liquidity has recently been supported by related‑party equity subscriptions and a $25.0 million Standby Equity Purchase Agreement, followed post‑quarter by a new 2026 SEPA of the same size. The company received a Nasdaq notice on April 14, 2026 for not meeting the $1.00 minimum bid price and reports ongoing material weaknesses in internal control over financial reporting.
OneMedNet Corporation (ONMD) filed a prospectus supplement for a mixed offering registering a primary sale of up to 11,500,000 shares of common stock and a secondary resale of up to 28,152,560 shares. The supplement incorporates the company’s Form 10-Q for the quarter ended June 30, 2026.
For Q2 2026, revenue was $0.3 million, up 88% year over year, driven by higher data delivery revenue as the business shifts to its real-world data platform, while legacy subscription revenue from the BEAM platform has ended. The company reported a net loss of about $2.2 million for the quarter and $4.6 million for the first half of 2026.
As of June 30, 2026, cash was approximately $0.4 million with total assets of about $1.4 million versus liabilities of $4.9 million, resulting in a stockholders’ deficit of roughly $3.5 million. Management states that these conditions raise substantial doubt about the ability to continue as a going concern and is relying on equity financing, including related-party subscriptions and standby equity purchase arrangements, to fund operations.
OneMedNet Corporation (ONMD) is asking stockholders at its fully virtual 2026 annual meeting on September 18, 2026 to approve several key items. Stockholders will vote to elect three Class III directors (Kenneth Alleyne, Sherry Coonse McCraw, and Jeffrey Yu) to three-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, approve an amendment and restatement of the 2022 Equity Incentive Plan adding 1,000,000 shares to the share reserve, and authorize the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-20.
As of August 11, 2026, OneMedNet had 59,286,450 shares of common stock outstanding and was out of compliance with Nasdaq’s $1.00 minimum bid price requirement, with a cure period running until October 12, 2026. The Board states that a reverse split may be used to help regain compliance and maintain the Nasdaq Capital Market listing. The equity plan currently has 826,417 shares available and 4,217,303 shares subject to outstanding RSUs, and the company estimates the newly requested plan shares equal about 1.7% of outstanding stock.
OneMedNet Corporation, a healthcare software company focused on real-world data from medical imaging, reported continued operating losses and liquidity pressure for the quarter and six months ended June 30, 2026. Revenue was modest but growing, with quarterly revenue of $0.3 million, up from $0.2 million a year earlier, driven by higher data delivery volumes on its iRWD platform after decommissioning its legacy BEAM subscription product.
Despite this growth, the company posted a quarterly gross loss of $0.6 million, an operating loss of $2.3 million, and a six‑month net loss of $4.6 million. Cash and cash equivalents were only $0.4 million against total liabilities of $4.9 million and a stockholders’ deficit of $3.5 million, and management states that these conditions raise substantial doubt about its ability to continue as a going concern.
The company funded operations through related‑party equity subscriptions and a 2024 Standby Equity Purchase Agreement, issuing additional shares and expanding its share count to 59.3 million common shares outstanding as of August 11, 2026. It exited all Bitcoin holdings, recorded gains from warrant and SEPA derivative remeasurements, and in July 2026 entered a new $25.0 million SEPA with Yorkville. OneMedNet also discloses noncompliance with Nasdaq’s $1.00 minimum bid price requirement and ongoing material weaknesses in internal controls over financial reporting.
OneMedNet Corp reported that director and 10% owner Thomas Kosasa purchased 1,449,275 shares of common stock on July 30, 2026. The $1,000,000 investment was made through a subscription agreement, with the shares priced at $0.69 each, based on the volume-weighted average price for the 10 trading days immediately prior to the purchase date. Following the transaction, he directly owns 18,538,150 shares.
OneMedNet Corporation is asking stockholders to vote at the virtual 2026 annual meeting on September 18, 2026. Stockholders will elect three Class III directors to serve until the 2029 meeting and ratify WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders are also asked to approve an amended and restated 2022 Equity Incentive Plan that increases the share reserve by 1,000,000 shares, bringing the fixed reserve to 3,357,223 shares before evergreen additions, and to approve a reverse stock split of the common stock at a ratio between 1-for-5 and 1-for-20, at the Board’s discretion, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement ahead of an October 12, 2026 deadline.
The Board recommends voting “FOR” all four proposals. The proxy explains how to attend and vote online, broker voting rules, quorum and vote standards (plurality for directors, majority of votes cast for other items), audit fee levels, and key terms of the equity plan, including no option repricing without stockholder approval and director compensation limits.
OneMedNet Corporation has set September 18, 2026 as the date of its 2026 Annual Meeting of Stockholders, with August 11, 2026 as the record date for stockholders entitled to notice of and to vote at the meeting.
Stockholder proposals for inclusion in the company’s proxy materials, other stockholder proposals, and nominations of director candidates must all be received by the Secretary of the company no later than August 5, 2026, in accordance with SEC Rule 14a-8, SEC Rule 14a-19 for any director election contest, and the company’s Bylaws.
OneMedNet Corporation is registering up to 11,680,535 shares of Common Stock for resale by existing holders. This includes up to 8,500,000 shares issuable under a $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville and shares previously issued to directors Dr. Thomas Kosasa and Dr. Jeffrey Yu (including stock issued in lieu of cash compensation).
The company will not receive any proceeds from these resales, though it could receive cash in the future from issuing SEPA shares. As of June 30, 2026, 56,952,652 shares were outstanding, and the registered shares equal about 18.1% of that amount, highlighting potential dilution and overhang. A 19.99% SEPA “Exchange Cap” (11,386,834 shares) and a 4.99% ownership limit apply absent stockholder approval.
OneMedNet reports net losses of $2.8 million in 2025 and $10.1 million in 2024 with an accumulated deficit of $104.4 million, and its auditors raise substantial doubt about going concern. The company also faces Nasdaq minimum bid-price noncompliance, extensive business and regulatory risks, and additional volatility from holding bitcoin.